Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
P 2 (2)
P 3 (1)

Trial Status

Not Yet Recruiting2
Recruiting2
Terminated1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07557446Phase 2Not Yet RecruitingPrimary

A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

NCT07062588Phase 2RecruitingPrimary

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07287241RecruitingPrimary

Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis Imperfecta

NCT06874166Not Yet Recruiting

Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders

NCT03638128Phase 3TerminatedPrimary

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Showing all 5 trials

Research Network

Activity Timeline